GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
GlobalRPh source record

Ceftazidime

Read renal action and limits
Local official-label summarySource retrieved 2026-09-05See the evidence for this drug6 sources available - open source summaries, references and comparisons

Fortaz / Ceftazidime / Tazicef

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (2)

Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist

Choose a source to read (6)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

2 additional source qualifications - review before use
Fortaz - product and source limitations

Excess exposure may cause encephalopathy, myoclonus or seizures. Verify the relevant dialysis schedule separately.

Before applying: Verify the current prescribing information for this presentation.

Tazicef - product and source limitations

High concentrations during reduced urine output can cause neurologic toxicity. Verify the indication and dialysis modality.

Before applying: Apply only to the stated formulation, indication and renal population.

Also check: Fortaz - product and source limitations; Tazicef - product and source limitations

Professional source

UCSF - ceftazidime

Choose a product and source Tazicef | Product label Fortaz | Product label Tazicef | GlobalRPh RX passage Fortaz | GlobalRPh RX passage All evidence
Product / population
Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.
Renal measure
CrCl in mL/min where specified; no equation inferred.
Source revision
Revision date not stated in the reviewed page.
Retrieved
2026-09-05 (not the revision date)

Dosing / renal protocol and limits

Short-infusion IV dosing by CrCl: >50, 2 g every 8 hours; 31-50, 2 g every 12 hours; 15-30, 2 g daily; <15, 1 g daily.

IHD: 1 g initially and following each dialysis. CVVHD: 2 g every 12 hours.

A separate specialist-selected extended-infusion strategy uses 2 g over 30 minutes as loading, then maintenance beginning 4 hours later. Maintenance infusions last 4 hours: 2 g every 8 hours above CrCl 50 or every 12 hours at 31-50. Below 31, use short infusion. CVVHD extended infusion also requires ID/pharmacy selection.

Source revision: Revision date not stated in the reviewed page. | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://idmp.ucsf.edu/content/ceftazidime

Scope: Locally included source-specific summary. Regimen differences are not automatically resolved. GlobalRPh v7.4.

Full source card / provenance

All sources, comparison tools and evidence navigation
Added / rechecked in v7.4

Read source findings

Read source-specific summaries and their qualifications. Retrieval date is not label revision date. Recent review does not imply clinical approval.

Official

Fortaz - labeled renal guidance

Retrieved: 2026-11-07
Source revision: DailyMed SPL version 9, posted Sep 13, 2019

Renal measure: Creatinine clearance (CrCl), mL/min

Read this dated source finding
Official

Tazicef - labeled renal guidance

Retrieved: 2026-11-07
Source revision: DailyMed SPL version 16, posted May 13, 2026

Renal measure: Creatinine clearance (CrCl), mL/min

Read this dated source finding
Rxlist

Fortaz - selected RX renal passage

Retrieved: 2026-11-07
Source revision: Mirror revision not established in the reviewed passage.

Renal measure: Use the renal measure explicitly present in the RX passage.

Read this dated source finding
Rxlist

Tazicef - selected RX renal passage

Retrieved: 2026-11-07
Source revision: Mirror revision not established in the reviewed passage.

Renal measure: Use the renal measure explicitly present in the RX passage.

Read this dated source finding
See all retained evidence sources
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 2 source difference / applicability notes

Official product label

Fortaz - labeled renal guidance

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Ceftazidime (Fortaz), IM or IV injection

Renal method: Creatinine clearance (CrCl), mL/min
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference
GlobalRPh RX List

Tazicef - selected RX renal passage

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Ceftazidime (Tazicef), IM or IV injection

Renal method: Use the renal measure explicitly present in the RX passage.
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Fortaz - product and source limitationsTazicef - product and source limitations

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 2 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

Source scope / renal recommendation differences

Fortaz - product and source limitations

Excess exposure may cause encephalopathy, myoclonus or seizures. Verify the relevant dialysis schedule separately.

How to use this: Verify the current prescribing information for this presentation.

Fortaz - labeled renal guidanceFortaz - selected RX renal passage

Selected renal passages reviewed; independent clinician adjudication pending.

Source scope / renal recommendation differences

Tazicef - product and source limitations

High concentrations during reduced urine output can cause neurologic toxicity. Verify the indication and dialysis modality.

How to use this: Apply only to the stated formulation, indication and renal population.

Tazicef - labeled renal guidanceTazicef - selected RX renal passage

Selected renal passages reviewed; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeFortaz - labeled renal guidanceTazicef - labeled renal guidanceFortaz - selected RX renal passageTazicef - selected RX renal passageUCSF - ceftazidime
Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. Read the original source for its complete context: https://globalrph.com/renal/ceftazidime/

Usual Dosing (Adults)

Usual: 1 to 2 grams IV every 8 to 12 hours. Severe: 2 grams IV every 8 hours.

Source dosing table:

IndicationDoseInterval
Usual adult1 g IV/IMEvery 8 to 12 hours
Uncomplicated urinary tract250 mg IV/IMEvery 12 hours
Bone and joint2 g IVEvery 12 hours
Complicated urinary tract500 mg IV/IMEvery 8 to 12 hours
Uncomplicated pneumonia or mild skin/skin structure500 mg to 1 g IV/IMEvery 8 hours
Serious gynecologic or intra-abdominal2 g IVEvery 8 hours
Meningitis2 g IVEvery 8 hours
Very severe life-threatening infections, especially immunocompromised2 g IVEvery 8 hours
Cystic fibrosis lung infection due to Pseudomonas with normal renal function30 to 50 mg/kg IV; maximum 6 g/dayEvery 8 hours
Neonates 0 to 4 weeks30 mg/kg IVEvery 12 hours
Infants and children 1 month to 12 years30 to 50 mg/kg IV; maximum 6 g/dayEvery 8 hours

The higher pediatric dose is for immunocompromised patients, cystic fibrosis, or meningitis. In cystic fibrosis patients clinical improvement has occurred, but bacteriologic cures cannot be expected in chronic respiratory disease and cystic fibrosis.

GRPH-ceftazidime-01 · Source section: Usual Dosing (Adults)Renal section finder

Renal Dosing

CrCl (mL/min)Dose
>50No change
31 to 501 g every 12 hours
16 to 301 g every 24 hours
6 to 15500 mg every 24 hours
<5 or dialysis500 mg every 48 hours

All renal doses may be increased by 50% in severe infections, as stated in the source.

GRPH-ceftazidime-02 · Source section: Renal DosingRenal section finder

Hemodialysis

1 g loading dose, then 1 g after each hemodialysis session. Alternative: 1 g every 48 hours plus 1 g after each hemodialysis.

CAPD: 1 g once, then 500 mg every 24 hours.

GRPH-ceftazidime-03 · Source section: HemodialysisRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Fortaz - labeled renal guidance

Open original reference

Open / share this exact local source

DailyMed / product prescribing information · Ceftazidime (Fortaz), IM or IV injection

Renal method: Creatinine clearance (CrCl), mL/min
Source date: DailyMed SPL version 9, posted Sep 13, 2019
Retrieved: 2026-11-07

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: General

Reduce maintenance dosing for impaired renal elimination. Select dose and interval using the adult renal table, the infection severity, and the organism's susceptibility. Excess exposure may cause encephalopathy, myoclonus or seizures. Verify the relevant dialysis schedule separately.

RDM74-fortaz-official-1 · Source locator: Renal guidance: General

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78982c98-7866-49f1-989f-a289c4242358
Retrieved
2026-11-07
Renal-function method
Creatinine clearance (CrCl), mL/min
Source date/version
DailyMed SPL version 9, posted Sep 13, 2019
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
8e28d393cf98911ddf926499fd051fef26b74a8307e43fa75dce8c25835454fb
Official

Tazicef - labeled renal guidance

Open original reference

Open / share this exact local source

DailyMed / product prescribing information · Ceftazidime (Tazicef), IM or IV injection

Renal method: Creatinine clearance (CrCl), mL/min
Source date: DailyMed SPL version 16, posted May 13, 2026
Retrieved: 2026-11-07

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: General

Adjust ceftazidime maintenance for impaired clearance. Match the schedule to kidney function, infection severity, and organism susceptibility. High concentrations during reduced urine output can cause neurologic toxicity. Verify the indication and dialysis modality.

RDM74-tazicef-official-1 · Source locator: Renal guidance: General

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=40d48c5d-650e-461b-a67b-7e65772d1b92
Retrieved
2026-11-07
Renal-function method
Creatinine clearance (CrCl), mL/min
Source date/version
DailyMed SPL version 16, posted May 13, 2026
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
c00a4eac22728e3c0540a1f0064d6aebdd4e34859e0d361d00653b22cd7ec4c1
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

Fortaz - selected RX renal passage

Open original reference

Open / share this exact local source

GlobalRPh RX List / product-label mirror · Ceftazidime (Fortaz), IM or IV injection

Renal method: Use the renal measure explicitly present in the RX passage.
Source date: Mirror revision not established in the reviewed passage.
Retrieved: 2026-11-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

RX List: selected renal passage

The mirror warns of neurotoxicity from high concentrations when usual dosing continues during renal impairment.

RDM74-fortaz-rxlist-1 · Source locator: RX List: selected renal passage

Source-specific limits

This mirror and the underlying product label share a source family.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/fortaz-drug/
Retrieved
2026-11-07
Renal-function method
Use the renal measure explicitly present in the RX passage.
Source date/version
Mirror revision not established in the reviewed passage.
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
35ee67d187ee4ae47af7bb1306383351e73eb808a09750c25e7aebfa671f56f0
Rxlist

Tazicef - selected RX renal passage

Open original reference

Open / share this exact local source

GlobalRPh RX List / product-label mirror · Ceftazidime (Tazicef), IM or IV injection

Renal method: Use the renal measure explicitly present in the RX passage.
Source date: Mirror revision not established in the reviewed passage.
Retrieved: 2026-11-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

RX List: selected renal passage

The mirror directs a lower total daily dose in renal insufficiency and describes neurologic toxicity with excess exposure.

RDM74-tazicef-rxlist-1 · Source locator: RX List: selected renal passage

Source-specific limits

This mirror and the underlying product label share a source family.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/tazicef-drug/
Retrieved
2026-11-07
Renal-function method
Use the renal measure explicitly present in the RX passage.
Source date/version
Mirror revision not established in the reviewed passage.
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
1960e94591605f5b651dd36c68bdf0fdf5df660923d4564597df82a325724cfc
Separate professional-source layer

University and professional protocols

Professional

UCSF - ceftazidime

Open original reference

Open / share this exact local source

UCSF Infectious Diseases Management Program · Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: CrCl in mL/min where specified; no equation inferred.
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Short-infusion IV dosing by CrCl: >50, 2 g every 8 hours; 31-50, 2 g every 12 hours; 15-30, 2 g daily; <15, 1 g daily.

IHD: 1 g initially and following each dialysis. CVVHD: 2 g every 12 hours.

A separate specialist-selected extended-infusion strategy uses 2 g over 30 minutes as loading, then maintenance beginning 4 hours later. Maintenance infusions last 4 hours: 2 g every 8 hours above CrCl 50 or every 12 hours at 31-50. Below 31, use short infusion. CVVHD extended infusion also requires ID/pharmacy selection.

RDM30-004-ceftazidime-1 · Source locator: UCSF - ceftazidime; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://idmp.ucsf.edu/content/ceftazidime
Retrieved
2026-09-05
Renal-function method
CrCl in mL/min where specified; no equation inferred.
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
3eb9c9538c9cdf800c1110f1375ef9df2a84c767329b4f85b38f28507a9c93c3

Provenance and preservation

Additional summaries stored on this page: 2 official-label, 2 RX List, 1 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/ceftazidime/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph individual
Local text SHA-256
cc0ba54d22ad755d40787a7e30557907c12a60ffe42806901efa0f90196a05f2
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report
Top